Xinghe Corporation

Xinghe Corporation, primarily operating as Xinghe Biotech, is a Chinese biopharmaceutical company focused on the development of innovative therapies for oncology and autoimmune diseases. The company maintains a diverse pipeline of small molecule inhibitors and monoclonal antibodies targeting well-validated pathways such as EGFR, VEGFR, and PD-1. Xinghe is actively advancing several candidates through clinical trials in China, aiming to provide more effective treatment options for prevalent conditions like non-small cell lung cancer and rheumatoid arthritis. Beyond its internal R&D, the company leverages strategic partnerships to enhance its manufacturing and commercialization capabilities within the Asian market.